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ABSTRACT
This study presents 25 cases of recurrent respiratory papillomatosis (RRP) that occurred 
in Sao Luis, Maranhao State, Northeast region, Brazil, between January 2007 and December 
2018. Sociodemographic and clinical profile of patients as well as human papillomavirus 
(HPV) infection status were evaluated. Clinical and histopathological data were collected 
from the patients’ medical records. For the HPV infection analysis, DNA was extracted 
and subjected to amplification by a nested polymerase chain reaction. Viral genotyping was 
performed by automated sequencing. The median age of patients was 12.40 ± 12.6. years, 
and the juvenile form of the disease (68%) was the predominant form of disease. Female 
participants were predominant (60%), and they were from cities located in the interior of 
the State (60%). The most common clinical manifestation was dysphonia; recurrence was 
observed in most cases (56%), and tracheostomy was necessary in seven patients (26.9%). 
When comparing the RRP forms, patients in the juvenile-RRP group had higher recurrence 
rates and need of tracheostomy than those in the adult-RRP group. The viral genotyping 
analysis revealed that 47.8% of patients had low-risk HPVs, whereas 13.1% had high-risk 
HPVs, and in 39.1% of patients the viral genotype was not obtained. HPV-6 was the most 
prevalent type and Juvenile-RRP was more prevalent in our population. HPV was present 
at a high rate, and HPV-6 was the predominant genotype. This study serves as the basis 
for further studies to be conducted in the Brazilian population. Our findings aid the better 
understanding of RRP, possibly suggesting some prognostic factors associated with the 
disease aggressiveness.
KEYWORDS: Recurrent respiratory papillomatosis. Human papillomavirus. Genotype. 
Larynx.
INTRODUCTION
Recurrent respiratory papillomatosis (RRP) occurs in children and adults. It 
is the most common benign neoplasm in children and has a high recurrence rate 
that negatively affects the patient’s quality of life, leading to higher healthcare 
expenses1. 
RRP is characterized by the development of exophytic proliferative lesions of 
the connective tissue covered by epithelium, which occur in the airway mucosa. 
Although papillomas can be present anywhere along the respiratory tract, they 
occur mainly on the larynx2,3. 
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This condition is initiated by a human papillomavirus 
(HPV) infection, especially the ones caused by low-risk 
genotypes such as HPV-6 and HPV-112,4. Highly oncogenic 
genotypes such as HPV-16 and HPV-18 are implicated in 
less than 5% of the cases5,6. In children, studies have shown 
that transmission may occur during the intrauterine life or 
during a vaginal delivery5. In adults, infection is likely to 
occur through oral sex2.
According to the patient’s age, RRP can be classified as 
juvenile-RRP when it occurs in individuals aged ≤12 years 
old and adult-RRP when it affects individuals aged 
>12 years7,8. Juvenile-RRP is generally more aggressive 
due to the rapid growth of multiple lesions with possible 
airway obstruction, recurrence and metastasis2,9. Adult-RRP 
is usually characterized by a non-aggressive solitary lesion 
with low recurrence rates10,11.
The course of disease is unpredictable, ranging from 
spontaneous remission to aggressive disease progression, 
which can spread to the lungs, requiring multiple surgical 
interventions9,10. Patients with RRP usually present non-
specific symptoms of airway involvement, including 
chronic cough, hoarseness, voice change and breathing 
difficulties3,12. Because of the unspecified clinical scenario, 
the disease can mimic other common laryngeal and 
respiratory diseases such as laryngitis, asthma, bronchitis 
and croup. Therefore, errors and delays in diagnosis and 
inadequate initial treatment are frequent1. 
Understanding the progressive nature of RRP and its 
potentially lethal consequences are critical to an effective 
intervention. Moreover, it is necessary to understand 
the characteristic symptoms that should raise an early 
suspicion of this condition, despite the relative rarity of 
the disease13.
This study was performed in the Northeast region of 
Brazil, an area with a high poverty index and low social 
indices14. Knowledge about the viral genotype present 
in RRP patients is vital to formulate therapeutic and 
prophylactic measures for the disease, such as vaccination. 
Based on the clinical description of the cases, it is expected 
to provide, together with other Brazilian studies, an estimate 
of the incidence of RRP in Brazil and to raise the awareness 
on the importance of RRP across the world. 
This study aimed to present cases of RRP that occurred 
at the University Hospital of Sao Luis city, Maranhao State, 
in Brazil, between January 2007 and December 2018. 
Molecular analysis was performed to detect and genotype 
HPV in addition to the patients’ clinical description. 
Statistical analysis was also conducted to assess the 
presence of associations between variables of the disease 
aggressiveness and the form of presentation of the disease 
(juvenile × adult) in this specific population.
MATERIALS AND METHODS
Study period and design
A retrospective cross-sectional study was conducted in 
patients who had juvenile- and adult-RRP between January 
2007 and December 2018.
Patients’ data and biological samples 
All details of RRP cases between 2007 and 2018 were 
collected from the histopathological records book of the 
Pathology Service. After surveying the number of cases, 
paraffin blocks containing the biological samples were 
retrieved from the pathology department. Data on the 
patients’ sociodemography, clinical and histopathological 
features were obtained from the medical records of the 
hospital and inserted into a protocol form for organizing 
data and subsequent analyses. 
The inclusion criteria were patients with RRP of any 
age org ender. The exclusion criteria included patients who 
had missing or incomplete medical records and/or paraffin 
blocks or those with paraffin blocks that were inappropriate 
to perform DNA extraction owing to poor quality. 
DNA extraction from Formalin‑Fixed Paraffin‑
Embedded (FFPE) tissue
Fifteen sections (approximately 5-µm thick) were 
prepared from blocks containing the surgical resection 
material and were used for DNA extraction. The sections 
were stored in 2.0-mL tubes at 4 °C until the next step, 
which corresponds to dewaxing.
The dewaxing process included the addition of 1 mL 
of Xylol P.A (Vetec, Rio de Janeiro, Brazil) to the sample, 
which was vigorously vortexed for approximately 10 s. The 
mixture was then subjected to centrifugation at 21,000 g for 
4 min, and this step was repeated three or four times. In cases 
in which the paraffin remained after this process, the sample 
was heated to 55 ºC. The supernatant was removed and 1 mL 
of ethanol P.A (Vetec, Rio de Janeiro, Brazil) was added, 
followed by vortex homogenization and centrifugation 
at 21,000 g for 6 min. Again, 1 mL of ethanol was added 
to the sample, followed by vortex homogenization and 
centrifugation at 21,000 g for 6 min. The supernatant was 
removed and the sample was centrifuged again at 21,000 g 
for 1 min to completely remove the ethanol. The tubes were 
left open and were incubated at 90 ºC in a thermomixer for 
1 min until the complete ethanol evaporation.
Total genomic DNA was extracted after the dewaxing 
process, as described in the QIAamp DNA FFPE Tissue 
Rev Inst Med Trop São Paulo. 2021;63:e63
Recurrent respiratory papillomatosis
Page 3 of 9
Kit protocol (QIAGENInc. Hilden, Germany). DNA purity 
and concentration were determined using the Nanovue 
spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA). 
HPV detection
To identify HPV DNA in samples, a polymerase chain 
reaction (PCR)-nested amplification was performed using 
the primers PGMY09 and PGMY11 for the first round and 
GP5+ and GP6+ for the second round15. 
Briefly, the PGMY09/11 reaction consisted of an initial 
denaturation step for 2 min at 95 °C followed by 40 cycles 
of denaturation for 40 s at 95 °C, annealing for 40 s at 55 °C 
and extension for 40 s at 72 °C. The final reaction volume 
was 25 µL, containing 10 pmol of each primer, 2.5 µL of 
10× buffer, 1.5 µL of 50 mM magnesium chloride, 10 mM 
dNTP and 0.2 µL of Platinum Taq Polymerase (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA)15.
The second round of amplification was carried out with 
primers GP5 + / GP6 + with an initial denaturation step for 
4 min at 95 °C, followed by 45 cycles of denaturation for 
45 s at 95 °C for 1 min, annealing at 40 °C for 1 min and 
extension for 1 min at 72 °C. At the end of the reaction, 
the final reaction volume was 25 µL, containing 10 pmol 
of each primer, 2.5 µL of 10× buffer, 1.5 µL of 50 mM 
magnesium chloride, 10 mM dNTP and 0.3 µL of Platinum 
Taq Polymerase (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA). Both rounds were performed in a 
Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, 
Waltham, MA, USA).
The  reac t ion  products  were  v isua l ized  by 
electrophoresis in 1.5% agarose gels prepared in TBE 
buffer. A 5-µL aliquot of DNA was homogenized in a 
loading buffer solution (Sigma-Aldrich, USA) and 0.1% 
Gel Red dye, and the entire mixture was applied to the 
gel. Electrophoresis was performed for 30-50 min at 5 
V/cm2 in a horizontal electrophoresis apparatus (Life 
Technologies, USA). The amplified DNA fragments were 
visualized in an ultraviolet light transilluminator (BIO-
RAD Laboratories, USA). 
HPV genotyping
HPV-positive PCR products were purified by using 
the Genelute PCR Clean-up kit (Sigma-Aldrich, USA), 
according to the manufacturer’s protocol. Automated 
sequencing was performed by the company ACTGene 
Molecular Analyses (UFRGS, Brazil) using the platform 
ABI 3500 (Thermo Fisher Scientific, Waltham, MA, USA). 
The purified samples were diluted using a 6-μL solution 
containing 30–60 ng of the purified amplification product, 
5 pmol of primer and double-distilled water. 
For the confirmation and identification of the HPV 
genotype, a comparison of the sequenced samples 
nucleotide sequences with GenBank prototypes by using 
the BLAST program. 
Statistical analysis
Samples’ data were submitted to the Shapiro-Wilk 
normality test, resulting in a normal distribution. The 
Student’s t-test for independent samples was used to analyze 
continuous variables. Discrete variables were presented as 
proportions. A univariate analysis was performed using the 
Fisher’s exact test to compare the proportions between the 
juvenile-RRP and adult-RRP groups. 
To verify if independent variables could predict 
the presentation of juvenile RRP, a crude analysis and 
one adjusted analysis were performed through a binary 
logistic regression model, considering only the variables 
that presented statistical significance (p <0.05). The 
Kaplan-Meier analysis was performed using the log-rank 
test to compare survival curves between the two groups. The 
dependent variable for the survival analysis was the period 
of follow-up going from the date of admission until the last 
date found in the medical record. The outcome of interest 
was the recurrent need for hospitalization. The time elapsed 
until the outcome was expressed in years. The survival 
time was analyzed using independent significant variables 
(p<0.05 in the univariate analysis). These analyses were 
performed using the SPSS® Statistics, version 24.0 (IBM 
Corp., Armonk, New York, USA).
Ethical approval
The study was approved by the Committee of Ethics and 
Research of the Federal University of Maranhao, document 
Nº 2935.566, in accordance with the Declaration of Helsinki 
for research in humans
RESULTS
Table 1 shows data on the social and clinical variables 
of the 25 patients included in the study, divided into the 
juvenile-RRP and adult-RRP groups. Most patients (68%) 
had the juvenile form of the disease, while 32% had the adult 
form. The mean age of the patients was 12.40 ± 12.6 years, 
with the sample composed mainly of female participants 
(60%), coming from cities in the interior of the State (60%).
The most common clinical manifestation was dysphonia, 
present in 80% of cases. Other manifestations such as 
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dyspnea and dysphagia were less common (36% and 
16%, respectively). Most patients (56%) had recurrence 
of lesions. Tracheostomy was performed in seven patients 
(26.92%).
The molecular evaluation showed that 92% (23/25) of 
the patients had HPV DNA.
When comparing the proportions between groups 
(juvenile-RRP X adult-RRP) through an univariate analysis, 
the variables age, recurrence of lesions and tracheostomy 
showed a 95% statistical significance level (Table 1). 
Patients in the juvenile-RRP group had higher recurrence 
rates and needed to undergo more tracheostomies than those 
in the adult-RRP group.
The univariate analysis performed using the Fisher’s 
exact test showed that the variables age, recurrence of 
lesions and tracheostomy could be included as predictive 
variables in the regression model, as they presented with 
statistical significance (p <0.05). However, the variable age 
was excluded, as it was used to divide the patients into the 
juvenile RRP and the adult-RRP groups.
Crude and adjusted analyses were performed using a 
binary logistic regression model. The variables analyzed for 
recurrent need of hospitalizations and tracheostomy were 
significant regarding the crude odds ratio; however, when 
adjusted for the variables in the binary logistic regression 
model, patients in the juvenile-RRP group did not show 
higher recurrence rates, but the need of tracheostomy 
was statistically higher in the juvenile RRP group when 
compared with the adult-RRP one (Table 2).
The variable tracheostomy was added as an independent 
variable to analyze the survival curve constructed using the 
Kaplan–Meier method. As it is a categorical variable, the 
dummy variable method was used assuming two values 
(0 or 1) to indicate the respective category, for tracheostomy, 
0 (No) and 1 (Yes) were considered for this procedure.
When evaluating the survival curves during the 
follow-up (in years), according to the medical records and 
considering the recurrence of hospitalizations as an outcome 
of interest, the probabilities of patients who underwent 
tracheostomy and who did not undergo tracheostomy did 




















































































































Data are presented as mean values, standard deviations and proportions; the Student’s t and the Fisher’ s exact test were used 
to compare the differences between both groups; a significance level of 95% was adopted; *p <0.05; SD = standard deviation; 
RRP = recurrent respiratory papillomatosis; HPV = human papillomavirus.
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not differ in the log-rank test (p = 0.5). The curve has also 
shown that there is no proportionality of risk during the 
observation period. This Schoenfeld residue assessment 
test confirmed this proportionality. Thus, there was no 
relationship between performing tracheostomy and the 
number of recurrences of the disease.
When the juvenile-RRP group was assessed separately, 
the age at the time of diagnosis ranged between 1 and 
12 years old, as shown in Table 3. Most patients (62.5%) 
(10) were diagnosed up to their fifth year of life, and 37.5% 
(7) were diagnosed after six years of age.
When we compared two groups of juvenile-RRP 
populations, namely, ≤ 5 years and > 5 years, we did not 
observe any statistically significant difference (Table 4).
Among the patients who had HPV DNA (92%), 47.8% 
had low-risk HPVs, whereas 13.1% had high-risk HPVs, 
and in 39.1% of the patients, it was not possible to determine 
the genotype by automated sequencing. The low-risk 
genotype, HPV-6, was predominant, followed by the low-
risk genotype, HPV 11. The high-risk genotypes HPV-16, 
HPV-51 and HPV-18 were found in one patient each.
DISCUSSION
This study presents the clinical and sociodemographic 
characteristics of patients with juvenile-RRP and adult-
RRP, as well as the detection and genotyping of HPV from 
papillomatous lesions. All the analyzed lesions were located 
in the laryngeal region.
The mean age of the patients at the time of diagnosis 
was 12.4 years (±12.6). This value is in accordance with 
that reported in the study of Seedat16 who observed a similar 
result in a population with RRP in South Africa, where the 
Table 2 - Risk assessment for the development of juvenile RRP infection.
Juvenile‑RRP
Raw odds ratio IC (95%) Adjusted odds ratio IC (95%) Wald P-value
Recurrence 0.139 (0.021‑0.938) 0.222 (0.029‑1.709) 2.088 0.1
Tracheostomy 0.588 (0.395‑0.876) 0.000 0.000 0.9
RRP = recurrent respiratory papillomatosis.
Table 3 - Age at the time of diagnosis in juvenile‑RRP cases.
































Mean (SD) 3.2 (±1.6)
SD = standard deviation; RRP = recurrent respiratory 
papillomatosis.
Table 4 - Comparison of social and clinical variables among 
juvenile‑RRP patients who were older or younger than 5 years 
old.
Juvenile‑RRP
≤ 5 years  
n = 10 (%)
> 5 years  
n = 7 (%) 
P
Gender 0.15
Female 5 (50) 6 (85.71)
Male 5 (50) 1 (14.29)
Origin 0.26
Capital 3 (30) 4 (57.14)
Interior 7 (70) 3 (42.86)
Dysphonia 0.66
Yes 9 (90) 6 (85.71)
No 1 (10) 1 (14.29)
Dyspnea 0.33
Yes 6 (60) 2 (28.57)
No 4 (40) 5 (71.43)
Dysphagia 0.5
Yes 1 (10) 0 (0)
No 9 (90) 7 (100)
Recurrence 0.59
1 2 (20) 3 (42.85)
≥5 8 (80) 4 (57.14)
Tracheostomy 0.13
Yes 6 (60) 1 (14.28)
No 4 (40) 6 (85.72)
HPV 0.41
Positive 10 (100) 6 (85.71)
Negative  0 (0) 1 (14.28)
The Student’s t and the Fisher’s exact test were used to compare 
the differences between both subgroups; a significance level 
of 95% was adopted; *p <0.05; RRP = recurrent respiratory 
papillomatosis; HPV = human papillomavirus.
Carvalho et al.
Rev Inst Med Trop São Paulo. 2021;63:e63Page 6 of 9
mean patient age was 13.3 years old. Two other African 
studies reported a lower mean age of 8.7 and 3 years of age, 
respectively17,18. In contrast, a Colombian study reported a 
mean age of 31.5 years19. 
Regarding the patients’ gender, there is no consensus 
in the literature about the prevalence of RRP according 
to the gender. Some authors reported a higher occurrence 
in males than in females, while others reported a similar 
prevalence rate between men and women17,20,21. In this study, 
females (60%) were predominant, but without statistical 
significance.
Juvenile-RRP was prevalent in this study, as in a 
Brazilian study conducted by Figueiredo et al.22 who 
have also observed that most lesions were located in the 
larynx. However, two other Brazilian studies conducted in 
Sao Paulo found a slight higher prevalence of adult-RRP 
with respect to juvenile-RRP, of 56% and 52.27%, 
respectively20,23. Chirilă and Bolboacă21, in a study carried 
out with 31 Romanian patients, have also observed a 
predominance of adult-RRP (58.06%). However, studies 
conducted in African regions have reported a higher 
prevalence of juvenile-RRP. Seedat24 observed that 84.7% of 
patients had juvenile-RRP in a population of South Africa. 
In 2004, Nwaorgu17, studying a Nigerian population, found 
the highest incidence of RRP in children of 6 to 10 years 
old, 95.3%of whom belonged to the lower social classes.
Many studies have shown that the occurrence of 
RRP is higher in populations with low socioeconomic 
status and low educational levels2. Derkay and Wiatrak25, 
Larson and Derkay26 and Venkatesan et al.27 observed 
that the prevalence of the disease is associated with a 
low socioeconomic level. Leung et al.28 assessed the 
association between the severity of juvenile-RRP and the 
socioeconomic status of Canadian children and observed no 
statistically significant correlation; however, they observed 
that more impoverished families were at a higher risk of 
developing the disease.
According to Larson and Derkay26, most juvenile-
RRP patients are diagnosed by the age of five. In this 
study, most juvenile patients were up to 5 years old at 
the time of diagnosis. A similar result was observed by 
Hermann  et  al.29, as five of nine patients with juvenile 
RRP (55.5%) were up to 5 years old. Buchinsky et al.30 
identified that the age at the time of diagnosis highlights 
the most aggressive or least aggressive clinical course. For 
these authors, the aggressiveness was high for children 
aged  <  5  years old. However, in this study, when we 
associated the age with aggressiveness variables, we did 
not observe any significant difference when compared to 
children aged > 5 years old. However, the small sample 
size in the present study may have caused this difference.
Several authors referred to dysphonia as the most 
common symptom, and dyspnea was the second most 
reported symptom in the literature among patients with 
laryngeal papillomatosis13,20. This is consistent with our 
findings, as dysphonia was the most common symptom 
among our patients, and dyspnea, was the second one. 
Ximenes et al.20 observed that dyspnea was more prevalent 
in the juvenile-RRP form than in adult-RRP. In this study, 
the prevalence was also higher in the youth population; 
however, this difference did not reach statistical significance. 
RRP aggressiveness can be assessed by the number 
of recurrences, age < 5 years, need of tracheostomy and 
the presence of HPV-1116,18,31. The recurrence rate found 
in our population was more prevalent in the juvenile-
RRP group than in the adult-RRP one (p=0.03) when 
applying the Student’s t test and the Fisher’s exact tests 
to compare the differences between both groups. These 
data are in agreement with those reported in literature. 
Ximenes Filho et al.20 observed that the general recurrence 
rate was 66%: 76.2% in the juvenile form and 56.5% in 
the adult form. Garcia-Romero et al.10 have also reported 
that the recurrence rate of individuals with the adult-
RRP form was 40%. However, when we performed more 
robust statistics, the recurrence variable lost its statistical 
significance.
The incidence of tracheostomy in patients with RRP 
as reported in the literature, ranges from 1.8% to 64%13,18. 
In the present study, it was observed that all the patients 
who required tracheostomy belonged to the juvenile-RRP 
group, corroborating data reported in the literature that 
found a greater aggressiveness of the disease in patients 
with juvenile-RRP32. The Student’s t and the Fisher’s exact 
tests were used to compare the differences between both 
groups (p = 0.04). However, as in the case of the recurrence 
variable, when a more robust statistical analysis was applied, 
tracheostomy has also lost its statistical significance.
HPV-DNA was found in almost all laryngeal 
papillomatosis lesions, similar to the results observed by 
Sanchez19 who reported a 95% prevalence of HPV-DNA in 
papillomatous lesions. The findings reported in other studies 
have also corroborated our results, confirming that HPV 
is the etiological agent of laryngeal papillomatosis10,20,33. 
Other studies have found that low-risk HPV genotypes, 
such as HPV-6 and HPV-11, are present in approximately 
90% of lesions, and only 10% of patients have high-risk 
genoypes1,10,26. In this study, low-risk oncogenic genotypes 
of HPV were prevalent in both juvenile-RRP and adult-RRP. 
HPV-6 was the most prevalent genotype in our population, 
corroborating the findings of other studies17,18,22,34. High-
risk oncogenic genotypes were observed in 16.7% of our 
patients.
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Matos et al.23 observed the presence of HPV-6 (72%) 
with respect to HPV-11 (28%) in 25 patients with laryngeal 
papillomatosis, in a Brazilian population. Eftekhaar et al.33 
observed a prevalence of 75% of HPV-6 in relation to 
HPV-11 (16.7%) in 12 Iranian individuals. In a Swedish 
study of 55 patients, Hocevar et al.35 found that 76% of 
patients were infected with HPV-6 and 24% with HPV-11. 
Garcia-Romero et al.10 showed the presence of HPV-6 in 
80% of patients and found that only 8% had HPV-11. We 
have also observed a prevalence of HPV-6 (63.6%) with 
respect to HPV-11 (36.4%) among RRP patients.
There are no studies evaluating the incidence of 
RRP in Brazil, but there are studies conducted in other 
countries, such as South Africa, Canada, United States, 
and Norway1,11,24,26. The cohort studies reported in the 
literature had relatively small sample sizes of RRP patients. 
Ximenes Filho et al.20 conducted a ten-year retrospective 
cohort study with 44 patients, while Matos et al.23 have 
also evaluated 25 patients with RRP, and in a third study, 
Silva et al.36 performed a ten-year retrospective study with 
21 patients. These three studies were carried out in Sao 
Paulo State. Recently, Mercuri et al.37 have estimated the 
incidence and prevalence of laryngeal papillomatosis in Sao 
Paulo State, Brazil. The results varied between 1.87-11.46 
and 6.86-22.92 per 1,000,000 inhabitants, respectively, for 
a total population of 11,871,852 inhabitants.
The Brazilian laryngeal papillomatosis studies are 
limited to Sao Paulo State. The present research is a 11-year 
retrospective cohort with a similar restricted sample size; 
however, it was conducted in the Northeast region of Brazil, 
which presents a lower human development index14. 
The automated sequencing technique was not effective 
for genotyping HPV in 39.1% of patients, which is a 
limitation of the study. This may be due to the presence of 
coinfections in these samples, which could have interfered 
with the virus detection, as described by Gharizadeh et al.37 
and Verteramo et al.38. 
CONCLUSION 
The present study was the first in Brazil to evaluate 
RRP in juvenile and adult patients living in the Northeast 
region of Brazil. In a total of 25 patients, the median age 
was 12.40 ± 12.6. years, the juvenile form of the disease 
(68%) was predominant, as was the female gender (60%) 
and patients coming from cities in the interior of Maranhao 
State (60%). Recurrence was observed in most cases 
(56%), and was more frequent in the juvenile RRP group. 
Tracheostomy was necessary in seven patients (26.9%) 
and was also more frequent in the juvenile RRP group. 
Viral genotyping showed that 47.8% of patients had low-
risk HPVs, whereas 13.1% had high-risk HPVs. The low-
risk HPV-6 was the predominant genotype. We hope that 
the information obtained in this research will enrich the 
Brazilian and the world literature on recurrent respiratory 
papillomatosis. 
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